{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:25:43Z","timestamp":1793805943202,"version":"4.6.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.06.029","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:56:54Z","timestamp":1787122614000},"page":"522-527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimal prostate-specific antigen thresholds for early salvage therapy after robotic-assisted radical prostatectomy"],"prefix":"10.1016","volume":"44","author":[{"given":"Jong Hoon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3030-0405","authenticated-orcid":false,"given":"Chung Un","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minyong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Hwan","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwang Gyun","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byong Chang","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Il","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Soo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.06.029_bib0001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0002","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/S0022-5347(05)66452-X","article-title":"Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?","volume":"165","author":"Amling","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0003","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0022-5347(01)69079-7","article-title":"Cancer control with radical prostatectomy alone in 1,000 consecutive patients","volume":"167","author":"Hull","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0004","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/01.ju.0000134888.22332.bb","article-title":"Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results","volume":"172","author":"Roehl","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12894-016-0146-6","article-title":"Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer","volume":"16","author":"Beauval","year":"2016","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0006","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","volume":"177","author":"Cookson","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0007","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0008","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/j.1464-410X.2009.09016.x","article-title":"Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database","volume":"105","author":"Moreira","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0009","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2013.08.022","article-title":"Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy","volume":"66","author":"Mir","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0010","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer-2024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0011","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0012","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0013","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/JU.0000000000003892","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part I: introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0014","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1464-410X.2011.10422.x","article-title":"The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up","volume":"109","author":"Antonarakis","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0016","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1200\/JCO.2005.04.0756","article-title":"Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition","volume":"24","author":"Stephenson","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0017","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.juro.2006.06.017","article-title":"Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality","volume":"176","author":"Freedland","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0018","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.eururo.2011.02.026","article-title":"Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence","volume":"59","author":"Boorjian","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1363009","article-title":"Ultrasensitive PSA: rethinking post-surgical management for node positive prostate cancer","volume":"14","author":"Aguiar","year":"2024","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2026.06.029_bib0020","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.3390\/biomedicines10092256","article-title":"Postoperative radiotherapy of prostate cancer: adjuvant versus early salvage","volume":"10","author":"Wegener","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0021","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ejca.2011.08.013","article-title":"Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling","volume":"48","author":"Ohri","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2026.06.029_bib0022","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.annonc.2024.03.010","article-title":"Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)","volume":"35","author":"Parker","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:29:06Z","timestamp":1793802546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1078143926005867"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.029","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal prostate-specific antigen thresholds for early salvage therapy after robotic-assisted radical prostatectomy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}